Cargando…

A Spectroscopic Approach to Investigate the Molecular Interactions between the Newly Approved Irreversible ErbB blocker "Afatinib" and Bovine Serum Albumin

The interaction of afatinib (AFB) with bovine serum albumin (BSA) was examined via fluorescence and UV-Vis spectroscopy. Spectrofluorimetric measurements revealed that AFB can strongly quench the BSA intrinsic fluorescence through producing a non-fluorescent complex. This quenching mechanism was tho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alanazi, Amer M., Abdelhameed, Ali Saber
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709191/ https://www.ncbi.nlm.nih.gov/pubmed/26751077 http://dx.doi.org/10.1371/journal.pone.0146297

Ejemplares similares

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report
por: Alshami, Jad, et al.
Publicado: (2015)

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
por: Modjtahedi, Helmout, et al.
Publicado: (2014)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
por: Lin, Nancy U., et al.
Publicado: (2012)

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
por: Gunzer, Katharina, et al.
Publicado: (2016)

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
por: Hoffknecht, Petra, et al.
Publicado: (2015)

Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017)

A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases
por: Zeller, Matthias, et al.
Publicado: (2017)

Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2
por: Ghosh, Chinmoy, et al.
Publicado: (2023)

Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
por: Mao, Xinfang, et al.
Publicado: (2016)

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
por: Ioannou, Nikolaos, et al.
Publicado: (2013)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
por: De Lorenzo, Claudia, et al.
Publicado: (2018)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR
por: Shen, Wang, et al.
Publicado: (2019)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
por: Benlimame, Naciba, et al.
Publicado: (2005)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli, Meysam, et al.
Publicado: (2019)

Spectroscopic and molecular docking studies reveal binding characteristics of nazartinib (EGF816) to human serum albumin
por: Almehizia, Abdulrahman A., et al.
Publicado: (2020)

Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin
por: Rasoulzadeh, F., et al.
Publicado: (2010)

Multi-spectroscopic characterization of bovine serum albumin upon interaction with atomoxetine()
por: Buddanavar, Arunkumar T., et al.
Publicado: (2017)

Multi-spectroscopic investigation of the binding interaction of fosfomycin with bovine serum albumin()
por: Meti, Manjunath D., et al.
Publicado: (2015)

Interaction of repaglinide with bovine serum albumin: Spectroscopic and molecular docking approaches
por: Pawar, Suma K., et al.
Publicado: (2019)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors
por: Oh, Yoon Sin, et al.
Publicado: (2011)

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012)

Quantitative Analysis of ErbB1 and ErbB2 Genes Amplification by a High Performance Liquid Chromatography
por: Rasti, Mozhgan, et al.
Publicado: (2014)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma
por: Jian, Hong, et al.
Publicado: (2019)

The interactome of human EGF/ErbB receptors
por: Uetz, Peter, et al.
Publicado: (2006)

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
por: Ather, Ferdows, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8e137mjpvdbqdaeh4ej23q7r9u